## IRB #3756: PHASE I TRIAL OF BUTYRATE AND GANCICLOVIR IN EBV-ASSOCIATED MALIGNANCIES

## FORM I: URINALYSIS FORM Screening

PATIENT ID#:	Center:
PATIENT INITIALS:	Form completed by:
	Date assessment completed:///

URINALYSIS		A. V	<sup>7</sup> alue					B. CS?* 1=Yes,Excludes 2=Yes, does not exclude 3=No 9=Not done	C. COMMENTS  Provide comments for any clinically significant value.
1. Specific Gravity				•					
2. pH						•			
3. Glucose	₀□ neg	₁□trace	<sub>2</sub> □prese	ent					
4. Protein	₀□ neg	₁□trace	<sub>2</sub> □prese	ent					
5. Ketones	₀□ absent	₁□trace	<sub>2</sub> □prese	ent					
6. Occult Blood	₀□ absent	₁□ present†							
	† If present, evaluate WBC, RBC, and epithelial cells below:								
7. WBC	₀□ none	₁☐few (1-5)	<sub>2</sub> □mod (6-10)			heav >10)	y		
8. RBC	₀□ none	₁□few (1-5)	<sub>2</sub> □mod (6-10)			heavy >10)	y		
9. Epithelial Cells	<sub>0</sub> none	₁☐few (1-5)	$_2 \square \mod$ (6-10)			]heav; >10)	y		

\*Column B

**CS** = Clinically significant abnormality

I\_urinescr.doc 01/13/99